|   From the Trenches

Heads Up And Eyes Wide Open

When your team’s priority is to execute a well-formed plan, then a “heads down” focus is critical. We all recognize this situation, using it to drive project management, accountability, and collaboration.

By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches features of LifeSciVC

Read more.


  |   From the Trenches

A Tale of Two Biotech Programs

From the first time I heard the story of the American chestnut, I was fascinated. It is a story with threads from history, ecology, conservation and biotechnology- it was difficult for a scientist who loves the outdoors not to get sucked in.

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

How Early Is Too Early To Establish A Commercial Function In Biotech?

After close to 20 years at Genentech (GNE) shaping and directing marketing and commercialization efforts for novel oncology therapies, I finally took the plunge leaving big Biotech to join a smaller early-stage biotech company called Replimune. Interestingly, several people (both internal and external) have asked me “why do you need a CCO or commercial function” at this stage? As I have been mapping out the first year of the commercial plan and road to launch for Replimune it’s become clear that you really can’t have a commercial seat at the table early enough. This was true at GNE/Roche where the organization worked hard over many years to include commercial perspectives for early assets beyond just a few words in the target product profile.

By Sush Patel, CCO of Replimune as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   Press Release

Atlas Venture Announces $300 Million Second Opportunity Fund

Atlas Venture, a leading early stage venture capital and venture creation firm investing in biotech innovation, today announced the closing of its second Opportunity Fund, raising $300 million in an oversubscribed fundraise. Atlas Venture Opportunity Fund II (AVOF II), will enable Atlas to continue its model of supporting its portfolio companies as they raise subsequent financings and advance therapeutic programs.

Read more.


  |   In the News

Atlas, Medicxi Invest $70M in Antibody for Obesity Licensed from Novartis

Science and industry have been working, for what seems like a lifetime, to come up with a safe and effective treatment for obesity.

Read more.